Fifty shades of gray: Bone disease in renal transplantation. (December 2015)

• Record Type: Journal Article
• Authors: Wong, Jiunn; Tan, Matthew Zhen-Wei; Chandran, Manju
• Other Names: Kee Terence Yi-Shern guest-editor.
• Is Part Of: Proceedings of Singapore healthcare. Volume 24:Number 4(2015)
• Page Start: 225
• Page End: 232
• Publication Date: 2015-12
• Subjects: Renal transplant -- bone health -- osteoporosis -- hyperparathyroidism -- chronic kidney disease; Medical care -- Singapore -- Periodicals; Medical care; Singapore; Periodicals; 362.1095957
• DOI: 10.1177/2010105815611808
• Languages: English
• ISSNs: 2010-1058

Abstract

Kidney transplantation is the renal replacement therapy of choice for patients with end stage renal disease. Advances in technology, surgical techniques and pharmacotherapy have improved renal allograft survival. Increasingly, we are seeing long term side effects related to renal transplantation, bone disease being a major one amongst them. Renal transplant patients have a higher risk of fragility fractures even when compared to those who remain on dialysis. This is likely to be related to pre-existing underlying bone disease and the emergence of new metabolic bone problems post-transplant. Conditions such as persistent hyperparathyroidism and the use of certain immunosuppressive agents have a deleterious effect on the post renal transplant bone. Remarkable advances in the field of metabolic bone research have been made in the last decade and newer imaging techniques, biomarkers and therapeutic options are now available for osteoporosis in the general population. Interest is being focused on attempting to extrapolate these new discoveries to the management of bone disease post renal transplant. This review will briefly describe the metabolic bone changes that occur after transplantation and will provide an update on the currently available investigative options and therapeutic strategies for the management of post renal transplant bone disease.